Postpartum Depression

Postpartum depression (PPD) affects approximately 10-20% of women after childbirth and is characterized by persistent sadness, anxiety, irritability, and impaired maternal functioning1. Early identification and comprehensive, evidence-based treatment are critical to improving outcomes for both mother and infant.

The APA emphasizes routine screening during the perinatal period using validated tools such as the Edinburgh Postnatal Depression Scale (EPDS) and recommends a multimodal treatment approach including psychotherapy particularly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT) and pharmacotherapy when indicated. Selective serotonin reuptake inhibitors (SSRIs) are considered first-line pharmacologic agents. 

The American Academy of Pediatrics (AAP) highlights the importance of integrating maternal depression screening into pediatric visits to facilitate early detection and intervention. Supporting new mothers’ mental health requires more than treatment; it involves psychoeducation to normalize symptoms and reduce stigma, psychosocial support to combat isolation, and coordination of care across obstetric, pediatric, and mental health services. Collaborative care models that engage multidisciplinary teams have demonstrated improved engagement and outcomes4

PPD risk is shaped by social determinants of health (SDoH) such as:

  • Poverty or financial stress
  • Lack of social support
  • Food or housing insecurity
  • Limited access to mental health care
Addressing these factors through screening, referrals, and community partnerships is essential to supporting mothers holistically.